The U.S. Food and Drug Administration issued a revision to draft guidance easing certain clinical pharmacokinetic testing requirements for biosimilars that use comparator biologics approved outside the U.S. The update aims to streamline biosimilar development and reduce redundant or unnecessary testing that hampers global development programs. The change follows earlier efforts to harmonize biosimilar pathways and address barriers from varying international approvals. FDA clarified when bridging studies are needed and signaled a willingness to accept foreign comparator data under defined circumstances to avoid duplicative clinical work. Sponsors and generics developers will welcome reduced regulatory friction; the move could accelerate biosimilar market entry and competition for high‑cost biologics.